Command Palette

Search for a command to run...

jenburkt-pharmaceuticals

1073.9-0.86%
Market Cap
₹0.00 Cr
Stock P/E
0.00
ROCE
0.00%
ROE
0.00%
Book Value
₹0.00

You might have missed

No Recent News

No recent news available for this stock.

Shareholding

Holdings
Distribution
Promoter
Institution
Public
Others

From Last Concall

No Concall Summary

Conference call summary is not available for this stock.

Peers Summary

Deep Value Pick

Jenburkt Pharmaceuticals Ltd. is currently undervalued with a low PE ratio and zero debt, but faces challenges in growth and profitability. Among its peers, it stands out as a potential value pick, despite having no growth metrics to show. Companies like Sun Pharmaceutical and Mankind Pharma exhibit strong profitability but are relatively overvalued, indicating an opportunity for investors to consider Jenburkt as a contrarian play.

Key Points
  • Jenburkt Pharmaceuticals has a low PE of 15.67 and zero debt, making it attractive from a valuation perspective.
  • The company lacks growth metrics, showing 0% revenue and EPS growth year-over-year and over three years.
  • Sun Pharmaceutical Industries and Mankind Pharma show strong profitability but are at higher valuation ratios, indicating potential overvaluation.
Top Performers
Sun Pharmaceutical Industries Ltd.

Highest revenue growth YoY at 8.42% and strong profitability metrics.

Mankind Pharma Ltd.

Strongest revenue growth of 18.12% YoY and high ROE of 23.15%.

Dr. Reddy's Laboratories Ltd.

High ROE at 21.76% and solid growth with 16.54% revenue increase YoY.

Leveling the playing field in markets.

© 2025 EQHQ Technologies Pvt Ltd

"Information provided is for educational purposes only and not financial advice.